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Abstract
Background:  Methicillin-susceptible  Staphylococcus aureus (MSSA) bacteraemia remains a
condition associated with considerable morbidity and mortality worldwide. It is a common but
little-studied problem outside of Europe and North America.
Methods: A single-centre retrospective case series profiling all patients with community onset-
MSSA bacteraemia presenting between March 2005 and February 2006 to a tertiary acute-care
university hospital in Singapore. In addition to epidemiological and clinical data collection, risk
factors for complicated bacteremia and attributable mortality were analysed.
Results: A total of 100 patients met the case definition. Patients were more likely to be male (65%)
and below 65 years of age (69%). Seventeen patients were intravenous drug abusers, while 38 had
diabetes mellitus. There were 18 cases of endocarditis, with 11 occurring in intravenous
buprenorphine abusers. Attributable mortality was 11%, and 46% of patients developed
complicated bacteremia. On multivariate analysis, age > 65 years and presence of chronic
pulmonary disease were the only significant risk factors for the former, while valvular heart disease
was a significant risk factor for the latter.
Conclusion: MSSA bacteraemia is associated with a significant risk of serious complications in
Singapore. Other Asian cities should be alert to the risk factors for adverse outcomes for this
important cause of morbidity and mortality.
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Background
Staphylococcus aureus bacteraemia remains a common
cause of mortality and morbidity both in spite of and as a
consequence of medical advances. Although the mortality
rate has declined in some countries as a result of improved
quality of care [1], the overall prevalence has increased in
line with increasing use of intravascular devices and an
expanding "at-risk" population [1,2].
The focus in recent years has been on infections caused by
methicillin-resistant  S. aureus (MRSA), especially with
regards to its clinical and economic impact in comparison
with methicillin-susceptible S. aureus (MSSA) [3,4]. The
rapid rise of infections caused by community-associated
MRSA (CA-MRSA) has further directed attention towards
MRSA [5,6]. Nevertheless, CA-MRSA is still relatively rare
on a global basis, whereas MSSA is a more common cause
of bacteraemia than MRSA in most parts of the world. The
incidence of MSSA bacteraemias is also not significantly
affected by the slew of infection control measures set in
place in most health care institutions.
Previous landmark studies had described the epidemiol-
ogy of MSSA bacteraemia and predictive factors for
adverse outcomes of infection [2,7-9]. However, epidemi-
ologic results are influenced by local factors, and commu-
nity-onset MSSA (CO-MSSA) bacteraemia is little studied
in Singapore and elsewhere outside of Europe and North
America. This study describes the epidemiology of CO-
MSSA bacteraemia and the risk factors for mortality and
complicated infections in patients seen at a university hos-
pital in Singapore, a modern Asian city.
Methods
Study Design
A retrospective chart review was conducted on all patients
with CO-MSSA bacteraemia hospitalised at the National
University Hospital – a 900-bed acute care tertiary aca-
demic hospital – between 1st March 2005 and 28th Febru-
ary 2006. The local ethics review board granted approval
for the study.
Subjects
The hospital microbiology laboratory generated a list of
all MSSA-positive blood cultures for the study period and
the patients' clinical charts were reviewed. A patient was
defined as having CO-MSSA bacteraemia if MSSA-positive
blood cultures had been drawn < 48 hours after hospital-
isation or if he/she remained symptomatic with no other
cause of infection found in the event that blood cultures
were positive > 48 hours post-hospitalisation.
Patients were further classified into either community-
acquired or healthcare-associated cases based on the crite-
ria proposed by Friedman and co-workers [10]. Patients
hospitalized for recurrent MSSA bacteremia or who had
polymicrobial bacteremia were excluded from the study.
Chart Review
A single investigator reviewed the patients' medical
records, collating epidemiologic and clinical data in a des-
ignated database. We used the diagnoses recorded by the
attending physicians, with the following exceptions:
pneumonia was defined by new pulmonary infiltrates on
a chest radiograph and isolation of MSSA from purulent
sputum (with leukocytes but no epithelial cells seen on
microscopy); endocarditis was defined strictly according
to the Duke criteria [9]; and urinary tract infection was
defined by a leukocyte count of ≥ 50 leukocytes/mm3 of
urine and a pure culture of MSSA yielding > 105 cfu/ml in
patients with the appropriate clinical presentation.
Appropriate empirical therapy was defined as the empiric
administration of antibiotics upon hospitalization to
which the consequent MSSA isolate was susceptible.
Suboptimal therapy was defined by any one of the follow-
ing: failure to initiate effective antistaphylococcal therapy
(cloxacillin or cefazolin; vancomycin if the patient was
allergic to penicillin) within 24 hours of a positive blood
culture result; suboptimal dosages of antibiotics (< 4 g per
day of cloxacillin or < 3 g per day of cefazolin; or their
equivalent paediatric dosages where appropriate); antibi-
otic duration of < 10 days for uncomplicated bacteraemia
and < 28 days for endocarditis, bone, joint or implant
infections; and failure to remove accessible foci of infec-
tion.
Outcomes Measured
The primary outcome measured was complicated bacter-
aemia. This was defined as the presence of either (1)
attributable mortality – this included all patients who
died with persistent signs and symptoms of infection in
the absence of another explanation for death, (2) compli-
cated infection at hospitalisation – new infection at a site
distant from the primary focus caused either by haema-
togenous seeding or direct extension of infection, or (3)
recurrent infection within a 12-week follow-up period.
This is similar to the primary endpoint used by Fowler and
co-workers with the exception that embolic stroke was not
included within this definition [7]. Patients with more
than one factor listed above were only counted once.
Secondary outcomes measured were attributable mortal-
ity and a composite variable comprising of complicated
and/or recurrent infection.
Statistics
Intercooled Stata (version 9.2) was used for statistical cal-
culations. Dichotomous variables were analysed with theBMC Infectious Diseases 2008, 8:14 http://www.biomedcentral.com/1471-2334/8/14
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χ2 test or Fisher's exact test as appropriate, and continuous
variables were analysed with Student's t test. Univariate
analyses of the association between individual variables
and outcomes were performed using logistic regression.
Variables with a P value of ≤ 0.20 on univariate analysis
were subsequently included in the corresponding step-
wise multivariate analysis. A P value of ≤ 0.05 was consid-
ered statistically significant.
Results
Of 126 patients with blood cultures positive for MSSA in
the study period, 100 fulfilled the criteria for CO-MSSA
bacteraemia. Forty-eight (48%) fulfilled Friedman's crite-
ria for healthcare-associated infection – the remainder
were community-acquired [10]. The median duration of
symptoms prior to hospitalization was four (range: 1 –
12) days. The details of the cases are listed in Table 1.
Thirty-one patients were above 65 years in age. Twenty-six
patients had central venous catheters – inserted for the
purposes of either outpatient hemodialysis (92.3%) or
chemotherapy (7.7%). One patient (1%) each had HIV
infection and liver cirrhosis. All 17 intravenous drug users
(IVDUs) reported abusing buprenorphine – 12 (70.6%)
and 5 (29.4%) were of Malay and Indian ethnicity respec-
tively. Fourteen (82.4%) IVDUs were male. All survivors
had been followed-up at the hospital outpatient clinics for
at least 12 weeks.
Although all but six patients received appropriate empiric
antibiotics upon hospitalization, optimal therapy as
defined previously was not received by 32 patients. This
included suboptimal antibiotics for 27 patients, and inap-
propriate dosage/delivery in 5 – oral cloxacillin at a dos-
age of 2 g per day had been used. The suboptimal
antibiotics used included vancomycin in 11 (40.7%)
patients who were not allergic to penicillin, ceftriaxone in
eight (29.6%), amoxicillin/clavulanate in two (7.4%),
levofloxacin in one (3.7%), and combinations of the
above in the remaining five (18.5%) patients. All eradica-
ble foci of infection, including central lines, abscesses, and
infected implants and joints were removed and/or
drained appropriately.
Patient outcomes, including causes of death other than
CO-MSSA bacteraemia and breakdown of complicated
infections, are listed in Table 2. Of the 46 patients with the
primary outcome of complicated bacteraemia, seven
(15.2%) were re-admitted for recurrent MSSA infection,
whereas 33 (71.7%) had complicated infection. Two of
eleven patients who died of MSSA bacteraemia and three
of seven patients re-admitted for recurrent MSSA infection
met the definition of having complicated infections at
first presentation. Eleven of 18 patients with infective
endocarditis were IVDU's. The crude mortality for patients
with CO-MSSA bacteraemia was 18%. Median duration of
stay among survivors was 11 days, with an inter-quartile
range of 20.5 days.
Results of univariate analysis of patient characteristics
with outcomes are shown in Table 3. Because suboptimal
therapy has no impact on the presence or absence of com-
plicated infections at presentation, the association of this
variable with the primary outcome was not calculated.
Patients with valvular heart disease or who abused intra-
venous buprenorphine were at higher risk of complicated
bacteraemia. Patients above 65 years of age and patients
with chronic pulmonary disease were more likely to die as
a consequence of CO-MSSA bacteraemia. Patients with
central intravenous catheters, who abused intravenous
buprenorphine, underwent hemodialysis, or who were of
non-Chinese ethnicity were more likely to develop a com-
plicated infection and/or recurrent infection.
On multivariate analysis, only the presence of valvular
heart disease (OR, 6.85; 95%CI, 1.21 – 38.72; p = 0.03)
was independently associated with complicated bacterae-
mia. Age > 65 years (OR, 13.66; 95%CI, 1.74 – 107.39; p
= 0.01) and chronic pulmonary disease (OR, 9.83;
Table 1: Descriptive characteristics of 100 patients with CO-
MSSA bacteraemia
Characteristic Value1
Age, years 49.7 ± 21.6
Gender, male 65
Ethnicity
- Chinese 51
- Malay 34
- Indian 12
- Others 3
Co-morbidities
- Diabetes mellitus 38
- Dialysis-dependent renal failure 28
- Presence of malignancy2 14
- Chronic pulmonary disease3 10
- Valvular heart disease 4
Other characteristics
- Intravenous drug abuse 17
- Presence of intravenous catheter4 26
- Previous hospitalisation5 53
Appropriate empiric therapy 94
Optimal antibiotic therapy 68
1Data are number or mean ± standard deviation
2 Includes both solid and haematologic malignancies
3 Includes chronic obstructive pulmonary disease, pulmonary fibrosis, 
and bronchiectasis
4 Central venous catheters only
5 Within 12 months of current hospitalisationBMC Infectious Diseases 2008, 8:14 http://www.biomedcentral.com/1471-2334/8/14
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95%CI, 1.56 – 62.05; p = 0.02) were independently asso-
ciated with attributable mortality. Inappropriate empiric
therapy (p = 0.13) and suboptimal therapy (p = 0.20) did
not appear to have any independent impact on attributa-
ble mortality. Intravenous drug abuse (OR, 5.54; 95%CI,
1.30 – 23.62; p = 0.02) was independently associated with
the development of complicated and/or recurrent infec-
tion.
Discussion
This is the first attempt to characterise CO-MSSA bacterae-
mias in Singapore. MSSA remains one of most common
causes of community-onset bacteraemias worldwide, as
evidenced by reports from Laos and Africa [11,12],
although there are no specific analyses of MSSA bacterae-
mia outside of Europe or North America. It is important
to note that 48% of the cases would fulfill criteria for
healthcare-associated infections [10]. However, this had
no independent impact on the outcomes measured.
Because up to 30% of the general population is colonized
by S. aureus, it is difficult to determine if patients with
healthcare-associated MSSA infections by definition are
actually infected by their own endogenous MSSA rather
than a transmitted healthcare-associated strain.
It is interesting to note that suboptimal therapy as defined
by Jensen and coworkers was not associated with mortal-
ity in our series [8]. It is possible that this is due to the
smaller sample size, but the fact that all eradicable foci
were removed from our patients and that 94% of patients
received empiric antibiotics active against MSSA probably
also contributed to the relative success of using subopti-
mal therapy.
One point of contention is the narrow definition of sub-
optimal therapy itself. Antibiotics such as amoxicillin-cla-
vulanate, levofloxacin, and ceftriaxone have in-vitro
activity against MSSA, but they are not recommended on
any published guidelines for the treatment of MSSA
bacteraemia. Although vancomycin is demonstrably infe-
rior to cloxacillin in the treatment of MSSA endocarditis
[13], it is less clear if this remains the case for the treat-
ment of uncomplicated bacteraemia. However, further
analyses (data not shown here) re-classifying these antibi-
otics as "optimal" for the treatment of MSSA bacteraemia
did not change the overall result that suboptimal therapy
had no impact on attributable mortality.
The skewed distribution of CO-MSSA bacteraemia cases
among the ethnic groups as compared with the national
demographic is partly contributed by the ethnic distribu-
Table 2: Outcomes of 100 patients with community-onset methicillin-susceptible Staphylococcus aureus bacteraemia
Outcome Number (%)
• No complications from bacteraemia 54
 Other cause mortality 7 (13.0)
é Acute myocardial infarction 3 (42.8)
é Liver failure 2 (28.6)
é Leukaemia/Lymphoma 2 (28.6)
• Complicated bacteraemia 46
 Attributable mortality 11 (23.9)
é Pneumonia 5 (45.4)
é No primary site 4 (36.4)
é Soft tissue infection 1 (9.1)
é Infective endocarditis 1 (9.1)
 Recurrent infection within 12 weeks 7 (15.2)
é Intravascular infection 3 (42.8)
é Soft tissue infection 2 (28.6)
é Infective endocarditis 2 (28.6)
 Complicated infection at initial hospitalisation1 33 (71.7)
é Infective endocarditis 18 (54.5)
é Soft tissue infection/necrotizing fasciitis 6 (18.2)
é Psoas/paravertebral abscess 6 (18.2)
é Vertebral osteomyelitis/disciitis 3 (9.1)
é Epidural abscess 3 (9.1)
é Other osteomyelitis 1 (3.0)
é Liver abscess 1 (3.0)
é Brain abscess 1 (3.0)
é Pulmonary abscess/Pneumonia 1 (3.0)
1 Some patients have multiple sites of infection. However, each case is only counted onceBMC Infectious Diseases 2008, 8:14 http://www.biomedcentral.com/1471-2334/8/14
Page 5 of 6
(page number not for citation purposes)
tion of the IVDUs [14]. A previous article had reported
that half of the intravenous buprenorphine abusers in Sin-
gapore were of non-Chinese ethnicity, although these
minorities make up only 25% of Singapore's population
[15]. The issue of health differentials in Singapore's differ-
ent ethnic groups has been highlighted for chronic dis-
eases [16], and now appears to be an issue for acute
infections as well.
The high incidence of endocarditis, much higher than in
the studies of Fowler and Jensen despite < 50% of local
patients undergoing echocardiography is a consequence
of the relatively large proportion of IVDUs in our series.
This highlights a separate social issue of buprenorphine
abuse in Singapore – itself a consequence of loose regula-
tory control over the drug in conjunction with stringent
and tightly enforced regulations on other intravenous opi-
ates – which at its height was responsible for more than 50
deaths over a two-year period [14]. New regulatory and
rehabilitation programs implemented since August 2006
should result in the decline of such cases over time [14].
Conclusion
As European and North American investigators have
found, community-onset S.aureus bacteraemia is associ-
ated with a significant morbidity and mortality, especially
in older individuals with co-morbidities in Singapore.
This highlights the need for continued research into treat-
ment advances and preventive strategies for S. aureus as a
whole, and not just for MRSA, in the rest of the world as
well.
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